secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2024-04-24T23:59:59+00:00
Accession:  0000885725-24-000040
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific Q1 beats: $3.856B sales +13.8%, adj EPS $0.56 vs $0.50-0.52 guide; raises FY outlook
--------------------------------------------------------------------------------

- GAAP net income $495M ($0.33 EPS) vs guide $0.29-0.31; adjusted EPS $0.56 vs $0.47 YoY and $0.50-0.52 guide.
- Net sales $3.856B, +13.8% reported (guide 7.5-9.5%), +15.0% operational, +13.1% organic (guide 7-9%).
- Cardiovascular +15.9% reported, MedSurg +10.3%; U.S. +12.7%, APAC +18.3%, Emerging Markets +22.6%.
- Launched FARAPULSE PFA in U.S.; FDA approved AGENT Drug-Coated Balloon; €2.0B notes for Axonics acquisition.
- FY2024 guidance: sales growth 11-13% reported, 10-12% organic; adj EPS $2.29-2.34; Q2 adj EPS $0.57-0.59.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000040/0000885725-24-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000040/bsx-20240424.htm
  HTML page:      https://secwatch.observer/filing/0000885725-24-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer